Lance Stewart, PhD MBA, CSOO
Institute for Protein Design, UW Medicine
University of Washington, Box 351655
Molecular Engineering and Sciences Building, 4th Floor
3946 W Stevens Way NE
Seattle, WA 98195-1655
Lance Stewart’s Tech Transfer and Advisory Roles
Lance Stewart’s conflict of interest management plan is provided by UW.
Lance Stewart is a Translational Advisor at the Institute for Protein Design = IPD-TA, Co-Founder = CF, Shareholder = S, or Advisor = A to the following companies. The first date on each line indicates the year of Company founding. (In parentheses are the dates & focus of Lance Stewart’s involvement).
PvP Biologics, Seattle WA 2013 (2014-2016, IPD-TA) Designed enzyme therapeutic for celiac disease.
Icosavax, Seattle WA 2017 (2017-present, IPD-TA) Designed protein nanoparticle vaccines.
Neoleukin Therapeutics, Seattle WA 2018 (2018-Q12019, IPD-TA, S) Designed proteins immunoncology.
A-Alpha Bio, Seattle WA 2018 (2018-present, A) Developing a fundamentally new way of supporting safer drug discovery.
Athira Pharma, Seattle WA 2012 (2014-present, S, A) Clinical stage development of regenerative therapeutics for neurodegenerative disease.
Tetra Discovery Partners, Grand Rapids, MI 2010 (2010-present, CF, S, A, Board Member 2013-present) Clinical stage development of therapeutics for cognitive impairment.
Companies licensing UW patents or for which Lance Stewart is a Co-Inventor:
PvP Biologics: Seattle / San Diego based company focused on the development of oral enzyme therapeutics for celiac disease, computationally designed enzymes that breakdown gluten in the stomach.
Icosavax: Seattle based company focused on development of a designed protein nanoparticle vaccine for respiratory syncytial virus (RSV) and other infectious diseases.
Seminars for companies not listed above)
Past companies with Lance Stewart serving as Translational Advisor at the Institute for Protein Design = IPD-TA, Co-Founder = CF, Shareholder = S, or Advisor = A.
Virvio (2016-2018, IPD-TA): Seattle based company started to pursue clinical development of anti-flu minibinders with unique and potent properties for neutralizing strains of influenza virus.
ImmuneDesign (2012-2013, A) A therapeutic vaccine product development company, acquired by Merck in 2019.
Emerald BioSolutions (2005-2011, CF, S, A) Liquid handling and reagent solutions for high-throughput structural proteomics, a subsidiary of deCODE genetics (2005-2009), protein crystallography reagents now sold by Rigaku, liquid handling hardware now sold by Protein Biosolutions.
Emerald BioStructures (1998-2013, CF, S, A) Gene to X-ray crystal structure in support of drug discovery and development, a subsidiary of Medichem Life Sciences (2000-2002), a subsidiary of deDODE genetics (2002-2009), spun out of deCODE (2009-2012), Beryllium (2012-2017), now a subsidiary of UCB Pharma.